Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). (Q36473943)

14 August 2017

1 reference

title

Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). (English)

1 reference

antiphospholipid syndrome

14 August 2017

1 reference

1 reference

systemic lupus erythematosus

1 reference

3

Y Shoenfeld

1 reference

14 August 2017

2

P L Meroni

1 reference

14 August 2017

R Cimaz

1

1 reference

14 August 2017

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

15

1 reference

14 August 2017

4

1 reference

14 August 2017

191-197

1 reference

Systemic antiphospholipid syndrome.

14 August 2017

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Lupus anticoagulant and late onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Frequency of anticardiolipin, antinuclear and anti beta2GP1 antibodies is not increased in unselected epileptic patients: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Antiphospholipid and glutamic acid decarboxylase antibodies in patients with focal epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Anticardiolipin and antinuclear antibodies in epilepsy--a population-based cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

High prevalence of antiphospholipid antibodies in children with epilepsy: a controlled study of 50 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Anti-cardiolipin and anti-beta2 glycoprotein I antibodies in Indian patients with systemic lupus erythematosus: association with the presence of seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Epileptic seizures in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Neurologic manifestations of the antiphospholipid syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Anti-beta 2-glycoprotein I antibodies bind to central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Evidence for bound antineuronal antibodies in brains of NZB/W mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Increased immunoglobulin binding to cerebral endothelium in patients with antiphospholipid antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Autoantibodies to phospholipids and brain extract in patients with the Guillain-Barre syndrome: cross-reactive or pathogenic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Antiphospholipid antibodies bind ATP: a putative mechanism for the pathogenesis of neuronal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Glutamic acid decarboxylase autoantibodies in controlled and uncontrolled epilepsy: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Serum antibodies in epilepsy and seizure-associated disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Autoantibodies and cell-mediated autoimmunity to NMDA-type GluRepsilon2 in patients with Rasmussen's encephalitis and chronic progressive epilepsia partialis continua

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Autoantibodies to NMDA receptor in patients with chronic forms of epilepsia partialis continua

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Autoimmune epilepsy: distinct subpopulations of epilepsy patients harbor serum autoantibodies to either glutamate/AMPA receptor GluR3, glutamate/NMDA receptor subunit NR2A or double-stranded DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Autoimmune epilepsy: some epilepsy patients harbor autoantibodies to glutamate receptors and dsDNA on both sides of the blood-brain barrier, which may kill neurons and decrease in brain fluids after hemispherotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

Antibodies to glutamate receptor subtype 3 (GluR3) are found in some patients suffering from epilepsy as the main disease, but not in patients whose epilepsy accompanies antiphospholipid syndrome or Sneddon's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2272RR

10.1191/0961203306LU2272RR

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16686257